Who we are
Board of Recommendation
How to Become a Member
Members’ Activities Calendar
What we do
Policy and Advocacy
Exchange the world
Introduction to IFMSA Exchanges
List of Participating Countries
Research Projects Database
Medical Students International
You are here:
(Bucharest) Molecular Techniques in the Diagnosis of Hematologic Diseases
Romania (FASMR) - University of Medicine and Pharmacy "Carol Davila", Bucharest
Center of Hematology and Bone Marrow Transplant Fundeni Clinical Institute, Bucharest, Romania
Prof. Dr. Daniel Coriu
Dr. Mihaela Dragomir
Type of Research Project
- Basic science
What is the background of the project?
Center of Hematology and Bone Marrow Transplant Fundeni (CHBMTF) remains the largest hematology center in Romania. It is affiliated to international scientific groups that work in the field of diagnosis and therapy: European LeukemiaNet, European Society of Hypertension, International Society of Amyloidosis. As the majority of patients admitted to Fundeni Clinical Institute suffer from malignant hematologic diseases. The doctors taking care of patients with these health problems have a great experience in autologous and unrelated allogeneic transplantation.
What is the aim of the project?
The purpose of this project is to contribute to deciphering the biologic and clinical diversity of hematologic neoplasia. Taking into consideration the center's reputation an the fact that it provides advanced molecular and biochemical testing and the diagnosis and monitoring of patients with hematologic malignancies, a large number of people from all over the country will be arriving at the institute .Therefore, it will help develop programs for students, physicians and residents following various specialisation and advanced programs in the clinical laboratory.
What techniques and methods are used?
1. Diagnosis and molecular monitoring in Chronic Myeloid Leukemia by Real Time Quantitative RT-PCR (RQ-PCR) and multiplex PCR 2. Diagnosis and molecular monitoring in Acute Lymphoid and Myeloid Leukemia by Real Time RT-PCR Quantitative (RQ-PCR) and Multiplex PCR Molecular Diagnosis in Hematological Diseases 3. Molecular diagnosis in thrombophilia 4. Molecular diagnosis in hereditary amyloidosis
What is the role of the student?
- The student will mainly observe
- The student will observe the practical experiments but will be highly involved in the analysis of the results
- The tasks will be done under supervision
What are the tasks expected to be accomplished by the student?
Preparation of cellular samples (TRIZol® Conservation) Isolation of RNA (Ribonucleic acid) fromTRIZol® Real-Time Quantitative PCR For Quantification Of BCR-ABL (RQ-PCR) Synthesis cDNA (complementary Deoxyribonucleic acid) by Reverse Transcription PCR (RT-PCR) These procedures will be shown to the student at the beginning of the project and during the 4 weeks he/she will be spending in the laboratory, he/she should be able to perform the procedures on their own, but under the supervision of his/her tutor.
Will there be any theoretical teaching provided (preliminary readings, lectures, courses, seminars etc)
What is expected from the student at the end of the research exchange? What will be the general outcome of the student?
- No specific outcome is expected
What skills are required of the student? Is there any special knowledge or a certain level of studies needed?
Basic laboratory skills PCR analysis along with the research team Clinical integration of the laboratory data Motivation Subjects passed: Molecular Biology, Physiology, Hematology
Are there any legal limitations in the student’s involvement
Type of students accepted
This project accepts: - Medical students
- Louis M. Staudt; M.D.; Ph.D. Molecular Diagnosis of the Hematologic Cancers N Engl J Med 2003; 348:1777-1785
- Tim P. Hughes; M.D.; Jaspal Kaeda; Ph.D.; Susan Branford; Zbigniew Rudzki; Ph.D.; Andreas Hochhaus; M.D.; Martee L. Hensley; M.D.; Insa Gathmann; M.Sc.; Ann E. Bolton; B.Sc.N.; Iris C. van Hoomissen; B.Sc.N.; John M. Goldman; D.M.; and Jerald P. Radich; M.D. Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia N Engl J Med 2003; 349:1423-1432
© 2015 - IFMSA.org - Developed by web agency